Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
MADRID — Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor, a phase III trial demonstrated. Final progression-free survival (PFS) analysis showed a 26% reduction in disease progression or death with belzutifan versus everolimus (Afinitor), despite an […]
Post-Immunotherapy Combo Promising in Advanced RCC
Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase inhibitor induced responses in nearly a third of advanced renal cell carcinoma (RCC) patients previously treated with immunotherapy, a single-arm phase II study found. In the study of 52 patients, 30.8% (95% CI 18.7-45.1) had a confirmed objective response following treatment with belzutifan […]